TY - JOUR T1 - Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 1838 LP - 1843 DO - 10.3174/ajnr.A4823 VL - 37 IS - 10 AU - R. Singh AU - K. Kesavabhotla AU - S.A. Kishore AU - Z. Zhou AU - A.J. Tsiouris AU - C.G. Filippi AU - J.A. Boockvar AU - I. Kovanlikaya Y1 - 2016/10/01 UR - http://www.ajnr.org/content/37/10/1838.abstract N2 - BACKGROUND AND PURPOSE: Recurrent glioblastoma currently has no established standard of care. We evaluated the response of recurrent glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab by using dynamic susceptibility contrast-enhanced MR perfusion imaging. We hypothesized that treatment response would be associated with decreased relative CBV and relative CBF.MATERIALS AND METHODS: Patients were accrued for this study from larger ongoing serial Phase I/II trials. Twenty-five patients (14 men, 11 women; median age, 55 years) were analyzed. Four distinct ROIs were chosen: 1) normal-appearing white matter on the contralateral side, 2) the location of the highest T1 enhancement in the lesion (maximum enhancing), 3) the location of highest relative CBV in the lesion (maximum relative CBV), and 4) nonenhancing T2 hyperintense signal abnormality surrounding the tumor (nonenhancing T2 hyperintensity).RESULTS: There was a statistically significant median percentage change of −32.34% (P = .001) in relative CBV in areas of maximum relative CBV following intra-arterial bevacizumab therapy. There was also a statistically significant median percentage decrease in relative CBF of −30.67 (P = .001) and −27.25 (P = .037) in areas of maximum relative CBV and maximum tumor enhancement, respectively. Last, a trend toward statistical significance for increasing relative CBV in nonenhancing T2 hyperintense areas (median percent change, 30.04; P = .069) was noted.CONCLUSIONS: Dynamic susceptibility contrast-enhanced MR perfusion imaging demonstrated a significant decrease in tumor perfusion metrics within recurrent glioblastomas in response to superselective intra-arterial cerebral infusion of bevacizumab; however, these changes did not correlate with time to progression or overall survival.BVbevacizumabDSC-MRPdynamic susceptibility contrast-enhanced MR perfusionGBMglioblastomamaxmaximumNAWMnormal-appearing white matterOSoverall survivalRANOResponse Assessment in Neuro-OncologyrCBFrelative cerebral blood flowrCBVrelative cerebral blood volumeSIACIsuperselective intra-arterial cerebral infusionTTPtime to progression ER -